Recent Advances in Immunotheragnostics: From Molecular Basis to Targeted Pharmaceutical Design

Dear Colleagues,

Within the last few decades, immunotherapy has gained an increasingly important role beyond standard therapies and is thus considered as the forth pillar of anti-cancer therapy. However, from a clinical perspective, not only an efficient treatment but also reasonable patient selection and therapy monitoring are highly required for improved patient outcomes. Recent advances in immunotheranostics can pave the way towards precision oncology and personalized medicine. The implementation of imaging tools before, during, or after immunotherapy, especially in the case of living drugs, can help predict and understand possible effects, as well as side effects of immunotherapy. Further, they can prospectively allow therapeutic interventions if needed. Precise and periodic target verification and assessment of molecular response to therapy can help decision-making and guide appropriate patient-specific treatment.

This Special Issue aims to provide a comprehensive overview of recent advances in cancer immunotheranostics and their significance for personalized medicine. Basic and translational original or review articles submitted to this issue may address various types of immunotherapeutics ranging from small molecules, peptides, nanoparticles, nanobodies, full-size, and recombinant antibodies to cells. Authors are encouraged to address topics including but not limited to biomedical research in the field of theranostic development, target and biomarker identification, novel targeted immunotheranostics, molecular in vivo imaging, or sophisticated combinatorial approaches for immunotherapy and tumor visualization.

Prof. Michael P. Bachmann
Dr. Anja Feldmann
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.